Assertio Holdings, Inc. (NASDAQ: ASRT) restored compliance with Nasdaq’s Minimum Bid Price Rule on January 12, 2026, after a one‑for‑fifteen reverse stock split that took effect on December 26, 2025. The split increased the share price to $1.00, meeting the rule’s requirement that a listed issuer maintain a bid price of at least $1.00 for ten consecutive trading days.
The reverse split consolidated 15 shares into one, preserving capital‑allocation flexibility while raising the per‑share price. By meeting the bid‑price threshold, Assertio eliminated the immediate delisting risk that had loomed since the stock fell below $1.00 in early 2025 and had been granted a 180‑day grace period until July 21, 2025.
Assertio’s strong third‑quarter 2025 performance underpinned the company’s ability to execute the reverse split. Revenue rose to $49.46 million, exceeding forecasts by 83 percent, and earnings per share reached $0.18, a beat of $0.27 against the consensus expectation of $0.09. The growth was driven by robust sales of the oncology drug Rolvedon, which outpaced prior‑year sales and helped offset headwinds in legacy product lines.
Following the compliance announcement, H.C. Wainwright raised its price target for Assertio to $35.00 from $3.00 and maintained a Buy rating, reflecting confidence that the company’s regulatory standing and recent earnings momentum position it well for future growth.
Regaining Nasdaq compliance removes a critical listing risk, stabilizes Assertio’s market presence, and signals to investors that the company can navigate regulatory challenges while delivering solid financial results. The reverse split, coupled with strong earnings, demonstrates management’s ability to protect shareholder value and maintain access to capital markets.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.